Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myeloma Survival Benefit May Help Amgen's Kyprolis Stave Off Competition

Executive Summary

Proving a survival benefit in the head-to-head ENDEAVOR relapsed multiple myeloma study gives Amgen's Kyprolis a leg up ahead of the entry of Velcade generics in the US this year.

You may also be interested in...



Amgen Focuses On Pipeline As Mature Products Face Declining Demand

Amgen ended its own development of the CETP inhibitor AMG 899, but will see if anyone else wants to license the drug. Meanwhile, the company is focusing on new drugs and assets in development to offset declining sales for Enbrel and other blockbusters.

ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma

Data supporting a role for J&J/Genmab's anti-CD38 monoclonal antibody in newly diagnosed multiple myeloma are "as good as could be expected," but the backbone regimen in the trial is rarely used in the US.

Amgen Beats Consensus, Raises Earnings Guidance, But Is It Sustainable?

Amgen's second quarter beat consensus estimates, but with only a $100m increase in sales and few major growth drivers expected in the near term, earnings growth may not last.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel